Medicina vs Alzheimer Prohibida en Europa
- A promising, yet controversial, scientific finding has emerged in the fight against Alzheimer's disease.
- The introduction of Lecanemab has not been without its challenges.
- In 2022, rather of the conventional route of publishing findings in prestigious peer-reviewed journals like Nature or Science, pharmaceutical companies Eisai and Biogen announced their findings regarding Lecanemab...
Lecanemab: A Divisive Hope in Alzheimer’s treatment?
Table of Contents
A promising, yet controversial, scientific finding has emerged in the fight against Alzheimer’s disease. Lecanemab, a drug showing potential effects against Alzheimer’s, has ignited a debate within the international medical community.
The Lecanemab Controversy: A Global Divide
The introduction of Lecanemab has not been without its challenges. While some countries have embraced this new treatment, others remain skeptical, leading to a meaningful divide in its global acceptance.
Early Announcement and Market Impact
In 2022, rather of the conventional route of publishing findings in prestigious peer-reviewed journals like Nature or Science, pharmaceutical companies Eisai and Biogen announced their findings regarding Lecanemab directly to the press. This move resulted in a surge in their stock market value, generating billions of dollars.
Clinical Benefits and Risks
The statistical improvements observed with lecanemab translate to a tangible clinical benefit. This means that a person with Alzheimer’s might maintain their independence longer and delay the need for residential care.A 27 percent reduction in cognitive decline offers valuable time in the progression of dementia.
Regulatory Approvals and Rejections
Timeline of Approvals
In 2023, pharmaceutical companies sought approval for Lecanemab in the United States, Japan, and Europe. Subsequently, a study published in the New England Journal of medicine detailed a trial involving 1,700 individuals. The study confirmed that Lecanemab reduces cognitive decline by 27 percent. However, the trial also reported two deaths.
The drug has since been approved in the United States, China, Japan, Israel, South Korea, and the United Arab Emirates. However, Europe rejected the drug, deeming that its benefits do not outweigh the risks of cerebral hemorrhages and the reported deaths of two patients.
Europe’s Stance
Europe’s rejection stems from concerns that the benefits of lecanemab do not adequately compensate for the risks, including cerebral hemorrhages and patient mortality. This decision highlights the cautious approach taken by European regulatory bodies in evaluating new Alzheimer’s treatments.
Call for Reconsideration
Despite the european rejection, four international researchers with decades of experience studying Alzheimer’s disease have urged Europe to reconsider its decision and approve this class of drugs, according to the Spanish newspaper El País.
A 27 por ciento significa ganar tiempo a la demencia.
The Global Landscape of Alzheimer’s Treatment
the situation in the fight against Alzheimer’s worldwide is complex. Some countries embrace new treatments like Lecanemab, while others remain hesitant. This divergence reflects differing perspectives on the balance between potential benefits and risks associated with novel therapies.
Lecanemab: Targeting Beta-Amyloid Plaques
Lecanemab (Leqembi®) is an antibody intravenous (IV) infusion therapy designed to target and remove beta-amyloid from the brain. It has received customary approval from the U.S.Food and Drug Governance (FDA) to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta.
Lecanemab is a mAb medication that is used to treat Aβ plaques, or more specifically, as an Aβ-targeting antibody to lessen their accumulation. On January 6, 2023, the FDA approved a novel drug, Lecanemab (marketed as Leqembi), with the intention of treating AD.
Lecanemab (Leqembi) is a medicine given to slow the progression of mild Alzheimer’s disease (AD). This medicine reduces clumps of proteins called amyloid-beta proteins that play a key role in AD. Reducing amyloid-beta proteins in the brain modestly slows memory and thinking decline from AD .
Current Status
As of march 11, 2025, the debate surrounding Lecanemab continues. The drug represents a significant advancement in Alzheimer’s treatment, but its risks and benefits require careful consideration.
- Efficacy: Lecanemab has shown a 27% reduction in cognitive decline in clinical trials.
- Risks: The drug is associated with risks, including cerebral hemorrhages and, in certain specific cases, death.
- Approval Status: Approved in the US, China, Japan, israel, South Korea, and the UAE, but rejected in Europe.
Lecanemab: Your questions Answered About This Alzheimer’s Drug
Lecanemab (Leqembi®) has emerged as a important, albeit controversial, new treatment for Alzheimer’s disease. As of March 11, 2025, teh medical community is still actively debating its benefits and risks. Hear’s a breakdown of what you need to know.
What is Lecanemab (Leqembi®) and How Does It Work?
Lecanemab is an antibody intravenous (IV) infusion therapy designed to target and remove beta-amyloid plaques from the brain. Beta-amyloid plaques are clumps of proteins that are believed to play a key role in the progression of Alzheimer’s disease. Lecanemab is designed as an amyloid-beta-targeting antibody to lessen their accumulation, with the intention of slowing the progression of mild Alzheimer’s disease (AD). it is a monoclonal antibody (mAb) medication.
Who is Lecanemab For?
Lecanemab is approved for use in individuals with early Alzheimer’s disease, including those with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, who have confirmed elevated levels of beta-amyloid in the brain. Lecanemab is not a cure for Alzheimer’s, but rather is intended to slow the rate of cognitive decline.
What Benefits Can Be Expected from Lecanemab?
Clinical trials have demonstrated that Lecanemab can reduce cognitive decline by 27% in individuals with early Alzheimer’s disease. This means that individuals taking Lecanemab may maintain their independence longer and potentially delay the need for residential care.
According to the Spanish newspaper El país, four international researchers, with decades of experience studying Alzheimer